Opus Genetics Advances OPGx-BEST1 Toward Phase 3
RESEARCH TRIANGLE PARK, N.C. — September 9, 2026 Opus Genetics, Inc. announced positive 3- and 6-month data from the...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RESEARCH TRIANGLE PARK, N.C. — September 9, 2026 Opus Genetics, Inc. announced positive 3- and 6-month data from the...
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
